Actuate Therapeutics, Inc.
ACTU Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$0.48
7.9%What Actuate Therapeutics, Inc. does
No business description yet.
- Legal name
- ACTUATE THERAPEUTICS, INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Accession · CIK
- 0001683168-26-002257
0001652935
Revenue and margins
Actuate Therapeutics, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Actuate Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 151.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably Actuate Therapeutics, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $3.0M | $8.6M | $13.2M |
| Interest coverage | −572.8x | −1,345.5x | −1,108.1x |
| Current ratio | 0.4x | 1.0x | 2.4x |
| Quick ratio | 0.4x | 1.0x | 2.4x |
| Total assets | $3.0M | $9.3M | $14.0M |
| Total liabilities | $8.4M | $9.2M | $6.1M |
| Shareholders' equity | −$99.6M | $0.1M | $7.9M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −104.1% | −88.4% | −25.9% |
| Altman Z'' | −191.38 | −64.16 | −41.61 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $21.7M | $18.7M | $10.3M |
| Operating income | −$25.0M | −$25.2M | −$22.5M |
| Interest expense | $0.0M | $0.0M | $0.0M |
| Income tax | $0.0M | $0.0M | $0.0M |
| Net income | −$24.7M | −$27.3M | −$22.2M |
| Diluted EPS | −$17.24 | −$3.26 | −$1.06 |
| Diluted shares | 0.00B | 0.01B | 0.02B |
| Cash flow | |||
| Cash from operations | −$21.6M | −$21.8M | −$19.2M |
| Stock-based compensation | $0.4M | $2.0M | $6.0M |
| Balance sheet | |||
| Cash and short-term investments | $3.0M | $8.6M | $13.2M |
| Current assets | $3.0M | $9.2M | $13.6M |
| Current liabilities | $6.9M | $8.8M | $5.7M |
| Total assets | $3.0M | $9.3M | $14.0M |
| Total liabilities | $8.4M | $9.2M | $6.1M |
| Preferred stock | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | −$99.6M | $0.1M | $7.9M |
| Returns | |||
| Return on capital employed | 636.3% | −4,877.0% | −270.1% |
| Return on equity | — | — | −553.7% |
| Return on assets | −826.0% | −443.2% | −190.4% |
| Return on tangible equity | — | −26,185.5% | −280.5% |
| Growth | |||
| Share count change | — | 483.5% | 151.1% |
| Financial health | |||
| Interest coverage | −572.8x | −1,345.5x | −1,108.1x |
| Current ratio | 0.4x | 1.0x | 2.4x |
| Quick ratio | 0.4x | 1.0x | 2.4x |
| Quality scores | |||
| Altman Z'' | −191.4 | −64.2 | −41.6 |
| Accruals ratio | −104.1% | −88.4% | −25.9% |
Source: SEC EDGAR XBRL filings (CIK 0001652935). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.